✦ LIBER ✦

Evaluation of Biologic End Points and Pharmacokinetics in Patients With Metastatic Breast Cancer After Treatment With Erlotinib, an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor

✍ Scribed by Rubio-Viqueira, B.; Hidalgo, M.

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Efficacy of Cetuximab After Treatment wi

✍ Jeffrey A. Meyerhardt; Denise Heseltine; Shuji Ogino; Jeffrey W. Clark; Peter C. 📂 Article 📅 2006 🏛 CIG Media Group, LP. 🌐 English ⚖ 147 KB

A Multicenter Phase II Trial of ZD6474,

✍ Dickler, M.N. 📂 Article 📅 2006 🏛 Elsevier Science 🌐 English ⚖ 59 KB

Phase I, pharmacokinetic (PK), and biolo

📂 Article 📅 2002 🏛 Elsevier Science 🌐 English ⚖ 139 KB

Phase I dose-finding and pharmacokinetic

✍ Noboru Yamamoto; Atsushi Horiike; Yasuhito Fujisaka; Haruyasu Murakami; Tatsu Sh 📂 Article 📅 2007 🏛 Springer 🌐 English ⚖ 367 KB

SAA1 is over-expressed in plasma of non

✍ Milan, Enrico; Lazzari, Chiara; Anand, Santosh; Floriani, Irene; Torri, Valter; 📂 Article 📅 2012 🏛 Elsevier 🌐 English ⚖ 791 KB

Efficacy and safety of erlotinib HCl, an

✍ A.N. GORDON; N. FINKLER; R.P. EDWARDS; A.A. GARCIA; M. CROZIER; D.H. IRWIN; E. B 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 175 KB